One patient can now cost your health plan more than every other member combined. Not over a lifetime. In a single plan year, from one prescription. Cell and gene therapies, the treatments that repair disease at the DNA level, carry list prices that start above two million dollars and climb past four. For a self-funded employer with a few hundred people on the plan, that is not a line item. It is a number larger than the entire annual health budget, and it can arrive with sixty days of notice.
Most mid-market employers still think of these treatments as science-fiction problems that belong to giant corporations. That framing is now out of date. The math below shows why, and what a 20-to-500-employee company can actually do about it before the claim lands rather than after.
- The FDA has approved roughly 40 cell and gene therapies, with list prices from $2.125 million (Zolgensma) to $4.25 million (Lenmeldy) per patient.
- A single $3.5 million therapy can exceed the entire annual health spend of a 100-person mid-market plan, which runs about $1.5 to $2 million a year at 2025 KFF premium benchmarks.
- A major stop-loss carrier's 2026 report finds $1 million-plus claims rose 46% from 2022 to 2026, and Segal's 2026 data shows stop-loss premiums up 12.7%, with gene therapy named as a top driver.
- Standard stop-loss does not automatically make you whole. Carriers increasingly carve out, exclude, or laser these treatments, and the gap hides in contract language most employers never read.
- The defense is contractual, not clinical: audit your stop-loss language, add a dedicated gene therapy program, and fix your plan document before a diagnosis forces the question.
What counts as a cell or gene therapy
The category covers treatments that change or replace genetic material to treat a disease at its source, plus therapies that re-engineer a patient's own cells. A gene therapy for hemophilia B delivers a working copy of a gene so the body starts producing a clotting factor it could not make before. A CAR T-cell therapy pulls a cancer patient's immune cells, reprograms them in a lab to hunt tumor cells, and infuses them back. One dose. Sometimes one cure.
The clinical promise is real, and for a family facing sickle cell disease or an infant with spinal muscular atrophy, these treatments can rewrite a life. The financial structure is what makes them different from anything your plan has priced before. There is no course of monthly infusions to budget across a year. The cost hits once, all at once, and it is enormous.
The number that should stop you cold
Here is what the FDA has already cleared for the U.S. market. These are manufacturer list prices, not negotiated net costs, but they set the ceiling your plan is exposed to.
| Therapy | What it treats | Approx. list price |
|---|---|---|
| Zolgensma | Spinal muscular atrophy (infants) | $2.125 million |
| Casgevy | Sickle cell disease | $2.2 million |
| Lyfgenia | Sickle cell disease | $3.1 million |
| Hemgenix | Hemophilia B | $3.5 million |
| Lenmeldy | Metachromatic leukodystrophy | $4.25 million |
Now set those prices against what a mid-market plan actually spends. The 2025 KFF Employer Health Benefits Survey puts the average annual premium at $9,325 for single coverage and $26,993 for family coverage. A 100-employee group with a typical mix of single and family enrollment runs somewhere between $1.5 million and $2 million in total health spending across a full year.
Hold those two facts next to each other. A single dose of Lenmeldy costs more than two times that entire annual budget. One Hemgenix claim runs close to double it. A Casgevy or Zolgensma case lands in the same range as everything else the plan pays for all year, combined. This is the insight that gets lost when gene therapy is filed under rare-disease trivia: at mid-market scale, one of these claims is not a spike in your trend line. It is a number that dwarfs the trend line entirely.
That is exactly the exposure stop-loss insurance is supposed to cap. Whether it actually does is the question almost no one asks until the diagnosis is already in the file.
This is not a rare-disease footnote anymore
Two things changed at once. The therapies got approved faster, and the claims data caught up. A major stop-loss carrier's 2026 high-cost claims report, built from more than 70,000 high-dollar medical claims across 3,300-plus self-funded employers, found that claims over one million dollars rose 46% between 2022 and 2026. The highest multimillion-dollar claims, driven by blood cancers like leukemia and lymphoma, averaged $5.45 million, and a single leukemia patient in 2025 generated a claim of nearly eight million.
A separate national carrier's stop-loss paid-claims analysis tells the same story from a different angle: claim incidence climbed to 32.5 per group measure, up from 23.8, a jump of roughly 37% in a single period. The treatments driving those numbers are the specialty drugs, biologics, and cell and gene therapies that carriers never modeled when they wrote their pricing three years ago.
The carriers noticed. Segal's 2026 medical stop-loss dataset, covering 225 health plans, shows the average stop-loss premium increase running at 12.7%, up from 9.7% the prior year. When Segal and market analysts break down what is pushing those renewals, two culprits sit at the top: GLP-1 medications for weight loss, and gene therapy. Reinsurance pricing behind the stop-loss market has moved up around 15% for 2026 on the same drivers. Your renewal is already paying for this risk whether or not a single employee ever needs one of these treatments.
If you want the fuller picture on who drives plan spend and why a small share of members carries most of the cost, our breakdown of high-cost claimants and what actually moves a health plan budget covers the underlying pattern.
The quiet gap in your stop-loss contract
Here is the trap. Most employers assume that once a claim clears their specific stop-loss deductible, the carrier pays the rest and the plan is protected. For a $3.5 million therapy against a $150,000 deductible, that assumption means the difference between a manageable loss and a solvency event.
The assumption is increasingly wrong, and the reasons hide in the contract:
- Outright exclusions. Some stop-loss contracts now exclude specific gene therapies by name, or exclude entire categories of cell and gene treatment. If your plan document covers the therapy but your stop-loss contract excludes it, you pay the full amount out of plan assets.
- Lasering. When a carrier knows a member is likely to need a high-cost treatment, it can raise that individual's deductible far above the group's, sometimes to seven figures, a practice the market calls lasering. The coverage still exists on paper. The reimbursement does not.
- Mismatched plan and stop-loss language. The most common failure is a plan document that promises to cover a treatment while the stop-loss policy defines it as experimental, investigational, or otherwise ineligible. That gap between the two contracts is where a seven-figure liability lives.
- Annual re-pricing at renewal. A therapy covered this year can be carved out, lasered, or repriced at your next renewal, right when a known diagnosis makes the risk concrete.
None of this is hidden fraud. It is standard risk management by carriers responding to a real cost curve. The point for an employer is that the protection you think you bought has to be confirmed in the language, not assumed from the premium. Our guide to how lasering and no-laser provisions work walks through the specific clauses to check.
A 2026 playbook to cap the exposure
The good news is that this is a contractual and structural problem, which means it has contractual and structural fixes. None of them require you to predict which employee will get sick. They require you to close the gap before the question is forced.
Read your stop-loss contract for cell and gene therapy language
Start where the money actually flows. Ask your broker or third-party administrator for the exact provisions governing gene therapy, cell therapy, and CAR T-cell treatment. You are looking for three things: are these treatments covered, is there a no-new-laser provision that stops the carrier from isolating a known case at renewal, and does the stop-loss definition of a covered treatment match your plan document word for word. If your broker cannot answer in specifics, that itself is the finding.
Add a dedicated gene therapy program
A market of specialized products now exists precisely because standard stop-loss struggles with these claims. Stand-alone gene and cell therapy stop-loss programs from carriers and managing general underwriters cover qualified CAR T-cell and gene therapy claims as a separate layer, often with per-treatment pricing that is far more predictable than absorbing the risk into your main policy. Some programs also route patients to manufacturer outcomes-based contracts, where the drugmaker refunds part of the cost if the therapy does not work as promised. For a mid-market plan, a dedicated carve-out can turn a catastrophic unknown into a modest, budgetable monthly cost.
Route treatment through centers of excellence and specialty management
Where care happens changes what it costs and how well it works. Steering these cases to designated centers of excellence, hospitals with deep experience in a specific therapy, improves outcomes and gives the plan access to negotiated case rates rather than open-ended billing. Pairing that with tight specialty drug oversight matters because many of these therapies are billed under the medical benefit, not the pharmacy benefit, which is exactly where plans lose visibility. Our overview of specialty drug management on the medical benefit explains how those claims slip through the cracks and how carve-out strategies close them, a theme we also cover in carve-out strategies for mid-market plans.
Fix the plan document before the claim, not after
Your plan document is the single most powerful lever you own, and it is the one employers touch least. Decide, in advance and in writing, how the plan handles cell and gene therapy: what it covers, under what medical criteria, through which network, and how it coordinates with your stop-loss policy. Align the two documents so there is no daylight between them. Doing this while no one on the plan has a diagnosis is a routine plan-design decision. Doing it after a diagnosis is a fiduciary minefield, because now every choice looks like it targets a specific sick employee.
How a $3 million claim actually reaches your desk
The exposure is not only about whether stop-loss covers the treatment. It is also about timing, and timing is where even a covered claim can squeeze a plan's cash. Here is the sequence most employers never see until they live it.
A member gets a diagnosis. The treating center seeks authorization for a therapy that costs more than a house. The claim is submitted, and under most stop-loss contracts the plan pays first and gets reimbursed after, sometimes weeks after, once the carrier reviews and approves the reimbursement. For a plan with a $150,000 specific deductible and a covered $3.5 million claim, that means your plan's bank account may need to front a large sum and wait to be made whole. A plan running lean on reserves can hit a cash crunch on a claim it is fully insured against, purely because of the gap between paying out and being paid back.
Two moves reduce that risk. First, ask whether your stop-loss carrier offers advance funding or simultaneous reimbursement on catastrophic claims, which some now do specifically because of gene therapy. Second, size your plan's reserve or aggregate protection with these timing gaps in mind, not just the annual expected spend. A treatment that cures a disease is a good outcome for everyone. It should not also be the week your plan cannot pay its other bills.
What this means at your group size
The risk does not scale evenly, and your response should match your headcount.
Under 100 employees. A single catastrophic claim can exceed your whole annual budget, so pooled protection is not optional. If you are fully insured or level-funded, confirm the carrier owns this risk entirely. If you are self-funded, a dedicated gene therapy stop-loss layer is the highest-value insurance dollar you can spend, because the alternative is a loss your cash reserves cannot absorb. This is part of why the decision to self-fund at a smaller group size deserves a hard look at tail risk, not just average savings.
100 to 250 employees. You have enough scale to self-fund and enough exposure to be seriously hurt by one claim. This is the range where the stop-loss contract audit and a dedicated carve-out program pay for themselves. Read the language, price a standalone gene therapy program, and align your plan document this renewal cycle.
250 to 500 employees. The probability that someone on your plan needs one of these treatments stops being remote and starts being a question of when. At this size you can negotiate no-new-laser provisions, build centers-of-excellence steerage into your plan design, and treat cell and gene therapy as a standing line in your risk model rather than a surprise. Our full stop-loss guide for self-funded employers lays out the contract structures worth negotiating.
The bottom line
Cell and gene therapies are one of the genuine medical advances of the decade, and they are also a financial exposure most mid-market plans have not priced. The list prices are public. The claims data is rising. The carriers have already moved. What remains is the one thing inside your control: confirming, in writing and before a diagnosis forces it, that a $3.5 million claim would be a covered event and not a company-ending one. That is a quiet afternoon with your broker now, or a crisis later. The employers who handle it early will barely notice when the claim comes. The ones who assumed their coverage held will find out the hard way that a premium is not the same as protection.
Related Reading
For more on managing catastrophic risk and specialty spend, explore these Benefitra articles:
- Stop-Loss Insurance for Self-Funded Employers: A Complete Guide
- High-Cost Claimants: Why a Few Members Drive Most of Your Spend
- Specialty Drug Management for Employer Health Plans
Frequently Asked Questions
Does standard stop-loss insurance cover gene therapy?
Not automatically. Many 2026 stop-loss contracts exclude specific gene therapies, cap them, or laser known cases by raising an individual member's deductible. Coverage has to be confirmed in the contract language, and the stop-loss definition of a covered treatment must match your plan document exactly. A premium payment alone does not guarantee reimbursement on these claims.
How much does a cell or gene therapy actually cost a self-funded plan?
FDA-approved therapies carry list prices from about $2.125 million (Zolgensma) to $4.25 million (Lenmeldy). What your plan pays depends on your stop-loss structure. With a covered claim and a $150,000 specific deductible, the plan's share is the deductible plus any gap in stop-loss terms. With an exclusion or a laser, the plan can be liable for the full amount.
Is my company too small to worry about this?
The opposite is true. A smaller plan has less premium and fewer reserves to absorb a single multimillion-dollar claim, so one case does proportionally more damage. A 100-person plan spends roughly $1.5 to $2 million a year on health coverage, which a single gene therapy claim can exceed on its own. Smaller groups need pooled or dedicated protection more, not less.
What is a gene therapy carve-out program?
It is a stand-alone stop-loss layer that covers qualified cell and gene therapy claims separately from your main policy, usually at predictable per-treatment pricing. These programs often add access to centers of excellence and manufacturer outcomes-based contracts, where the drugmaker refunds part of the cost if the treatment fails. For mid-market plans, a carve-out converts an unbudgetable catastrophic risk into a manageable monthly cost.
When should we address this?
Before anyone on the plan has a relevant diagnosis. Setting your coverage rules, aligning your plan document with your stop-loss contract, and pricing a carve-out are routine plan-design decisions when no specific member is involved. After a diagnosis, the same changes can look like they target a sick employee, which creates fiduciary and legal risk under ERISA. Early is cheap and clean. Late is neither.